AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05036343 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InPen®
Description: A smartpen that has been FDA approved for children with diabetes age seven years and older that uses an app on a smartphone to help calculate insulin doses using the amount of carbohydrates that will be consumed at a meal along with what the current blood sugar reading is, to give a correction dose as well. The InPen app also serves as a log book to record insulin doses given, blood sugar at the time of a meal, and amount of carbohydrate eaten.
Study NCT05990686 — intervention group
Intervention type: DRUG
Intervention: Tramadol Hydrochloride
Description: After routine pre-operative evaluation, standard monitors will be connected to the patients: pulse oximetery, noninvasive blood pressure and electrocardiogram and baseline parameter will be recorded (heart rate, mean arterial pressure and peripheral oxygen saturation). Intravenous (IV) line will be inserted for all patients, and IV fluid will be started.~Intravenous infusion of 15mg/kg paracetamol together with 1mg/kg tramadol will be started and to be finished before starting of induction of anaesthesia (induction agent will be Propofol 2mg/kg)
Study NCT05990686 — intervention group
Intervention type: DRUG
Intervention: Fentanyl injection
Description: After routine pre-operative evaluation, standard monitors will be connected to the patients: pulse oximetery, noninvasive blood pressure and electrocardiogram and baseline parameter will be recorded (heart rate, mean arterial pressure and peripheral oxygen saturation). Intravenous (IV) line will be inserted for all patients, and IV fluid will be started...Intravenous injection of 1microgram/kg fentanyl will be given to the patient followed by induction agents ( propofol 2mg/kg).~.
Study NCT06408376 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiological cord clamping
Description: Immediately after birth, the newborn with prenatal diagnosis of CDH will be placed on a mobile table, made to receive these patients in the delivery room, at the level of the mother's womb, leaving the umbilical cord intact and intubated. The patient will be gently ventilated (PIM 15/25 - PEEP 4 - Fio2 50%), until saturation >85% and HR>100 or 10 timed minutes have elapsed, whichever occurs first, the umbilical cord will be clamped.
Study NCT05325684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-L1 inhibitor
Description: Enrolled patients received durvalumab/ Atezolizumab plus chemotherapy or target therapy treatment (durvalumab,1000mg，iv, d1, 21day as a cycle; Atezolizumab,1200mg iv, d1, 21day as a cycle.)
Study NCT05363592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-L01 12.5/500 mg
Description: FDC tablet, 2 tablets at a time, oral administration
Study NCT05363592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alogliptin Benzoate 12.5 mg
Description: Alogliptin Benzoate 12.5 mg 2 tablets, at a time, oral administration
Study NCT05363592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin HCl XR 500 mg
Description: Metformin HCl XR 500 mg 2 tablets, at a time, oral administration
Study NCT05508438 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Transfemoral mitral-valve repair
Description: Transfemoral mitral-valve repair
Study NCT06101810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COMET
Description: information already included in arm/group descriptions.
Study NCT06101810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: information already included in arm/group descriptions.
Study NCT05636839 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: UVB treatment
Description: UVB treatment 3 times per week for 10 weeks
Study NCT05164471 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: verbrinacogene setparvovec
Description: FLT180a is a gene therapy intended to increase endogenous FIX production in adults with Hemophilia B
Study NCT05210725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 Mg Oral Tablet
Description: 2.5 mg rivaroxaban twice a day in addition to acetylsalicylic acid (80-00mg once a day, standard care).
Study NCT04747288 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Traditional Chinese Medicine pattern
Description: Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) and non AIDDES Healthy Controls subjects will take the Traditional Chinese Medicine pattern diagnosis.
Study NCT04747288 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Traditional Chinese Medicine tongue diagnosis
Description: Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) and non AIDDES Healthy Controls subjects will take the Traditional Chinese Medicine tongue diagnosis.
Study NCT04747288 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Heart rate variability
Description: Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the Heart rate variability.
Study NCT05249088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protocolised reduction of non-resuscitation fluids
Description: * Maintenance fluids are discontinued in participants with positive cumulative fluid balance who are not dehydrated~* Intravenous fluid and enteral water are given as needed to correct electrolyte disturbances~* Enteral nutrition with energy density of at least 2 kcal/ml is administered according to local practice~* Starting 72 hours after inclusion, glucose at a concentration of at least 20% and a maximal dose of 1g/kg/day may be used as nutrition if enteral feeding is not tolerated. Glucose at this dose or lower may be started earlier in patients with insulin dependent diabetes if enteral feeding is not tolerated and local protocol mandates this~* Parenteral nutrition is administered according to local protocol~* Intravenous medications are concentrated according to a predefined protocol~* Patients with neutral or negative cumulative fluid balance receive maintenance and other fluids such that total dose of fluids covers the daily need of water (about 1ml/kg/h)
Study NCT04747288 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Schirmer's test
Description: Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the Schirmer's test.
Study NCT04747288 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ocular Surface Diseast Index (OSDI)
Description: Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the Ocular Surface Diseast Index (OSDI).
Study NCT05249088 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Participants receive non-resuscitation fluids according to local routines, with the following stipulations:~* Maintenance fluids (crystalloids and/or glucose and/or enteral water) are given at a dose of 1 ml/kg/h unless local protocol states otherwise~* Glucose is used at maximal concentration of 10% unless local protocol states otherwise.~* Medications are concentrated according to local protocol
Study NCT04995328 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiation Care Gel
Description: The investigational medical product of this study is a hydrogel, Radiation Care® gel which increases moisturizing and it can be applied to the target areas including skin folds and creases.
Study NCT05212155 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: family-based behavioral treatment (FBT)
Description: Individual and group treatment of parent/child dyads to improve dietary choices, minimize sedentary behaviors, increase physical activity levels, and identify social support environments that reinforce healthy lifestyle choices.
Study NCT05649618 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes
Description: On day 0 patients will be intravenous infusion of TILs
Study NCT05649618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Part of the non-myeloablative lymphocyte-depleting preparative regimen
Study NCT05649618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide Capsules
Description: Part of the non-myeloablative lymphocyte-depleting preparative regimen.
Study NCT05649618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Following cell infusion, the patient receives high-dose bolus IL-2, which is dosed to individual patient tolerance.
Study NCT04747288 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI)
Description: Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI).
Study NCT04747288 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 36-Item Short Form Survey (SF-36)
Description: Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the 36-Item Short Form Survey (SF-36).
Study NCT05732246 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: First rib mobilization with balloon breathing exercises
Description: Patient was in the supine position, placing the soles of his feet against the wall so that the ankle, knee, and thigh joints are at a 90-degree angle. The subject placed a 3-4-inch ball between his/her knees, which he/she has to maintain through the pressure of the internal thigh muscles during the whole training period and puts his/her back on the bed. Holds the right hand above the head and the left hand with the balloon. Meanwhile examiner would palpate 1st rib with head in left side flexion. Patient was then asked to inhale through the nose in three-four seconds and then exhales slowly into the balloon. Then, holding the first rib in place, the patient was asked to inhale and exhale deeply again. The examiner continued applying pressure to hold the first rib in a position of relative depression during inhalation, and further depressed the first rib as able during exhalation.
Study NCT05054764 — intervention group
Intervention type: DEVICE
Intervention: Promus PREMIER BTK DES
Description: Collect one year data of the Promus PREMIER BTK drug eluting stent in CLTI patients
Study NCT05242640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindful attention
Description: Participants will listen to mindful attention audio recordings via headphones
Study NCT05242640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will complete a moderate-intensity walking program
Study NCT05242640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise with mindful attention
Description: Participants will complete a moderate-intensity walking program while listening to mindful attention audio recordings via headphones
Study NCT06223568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m\^2 will be administered over 60 (+/-10) minutes.
Study NCT06223568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75 mg/m\^2 will be administered over 120 (+/-10) minutes.
Study NCT06223568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRGN-2009
Description: PRGN-2009 will be administered in Arm 2 participants only as an SQ injection in the arm at a dose of 1 mL nominally containing 5x10\^11 viral particles (VP) on Day -7 (+/-3 days) of Cycle 1, Day 11 (+/-3 days) of Cycles 1, 2, and 3.
Study NCT06562608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticholinergic Deprescription
Description: per routine clinical care, people in the active arm of the study will undergo deprescription of benztropine or trihexyphenidyl per routine clinical care.
Study NCT06562608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No Anticholinergic Deprescription
Description: In this arm, no deprescription of benztropine or trihexyphenidyl will occur.
Study NCT06051604 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Mi-Helper
Description: The Mi-Helper device is a non-invasive, drug-free, novel therapy that uses a patented process of dry air flow across the nasal turbinates to induce a phase change (evaporation) that extracts energy (thermodynamics) causing local cooling which modulates nerves associated with pain and other symptoms of migraine. The device delivers a controlled pressure and flow of dry room temperature air along with a nebulized saline mist for added comfort and evaporative efficiency.
Study NCT06051604 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mi-Helper
Description: The Mi-Helper device is a non-invasive, drug-free, novel therapy that uses a patented process of dry air flow across the nasal turbinates to induce a phase change (evaporation) that extracts energy (thermodynamics) causing local cooling which modulates nerves associated with pain and other symptoms of migraine. The device delivers a controlled pressure and flow of dry room temperature air along with a nebulized saline mist for added comfort and evaporative efficiency.
Study NCT06375291 — intervention group
Intervention type: OTHER
Intervention: splint /steroid injection/both
Description: pregnant women treated in pain department by splint /steroid injection/both
Study NCT05329220 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABNCoV2
Description: ABNCoV2 100μg single dose
Study NCT05329220 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comirnaty
Description: Comirnaty
Study NCT05939063 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LRAMPS
Description: For LRAMPS procedure, Gerota's fascia and perirenal fat capsule are removed, and the procedure is divided into anterior LRAMPS and posterior LRAMPS depending on whether the left adrenal gland is resected. The N1 station lymph nodes (i.e., groups 10, 11, and 18) in the body and tail of the pancreas are removed. If the tumor is located near the pancreatic body, the No. 9 lymph node group is additionally removed.
Study NCT05939063 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LDP
Description: For LDP procedure, the dissection plane is located behind the fusion fascia. The N1 station lymph nodes (i.e., groups 10, 11, and 18) in the body and tail of the pancreas are removed. If the tumor is located near the pancreatic body, the No. 9 lymph node group is additionally removed.
Study NCT05732259 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Percussion therapy
Description: Participant lying in prone position on the couch will receive percussion therapy with Theragun PRO using standard ball head at speed of 1750 rpm, for total of 90 seconds, split into 3 sets of 30 seconds with 10 seconds rest.
Study NCT05732259 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Myofascial Release technique
Description: Manual myofascial release technique for 90 sec continuous.
Study NCT05420779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSL-1502 capsules(low dose)
Description: 350 mg each time, orally administered QD, every 3 weeks as a treatment cycle.
Study NCT05420779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSL-1502 capsules(high dose)
Description: 500 mg each time, orally administered QD, every 3 weeks as a treatment cycle.
Study NCT05420779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigator's choice of chemotherapy
Description: Capecitabine tablets, 1250 mg/m2 each time, BID oral administration; Vinorelbine tartrate injection, 25 \~ 30 mg/m2 each time, intravenous drip (15 \~ 20 min); Eribulin mesylate injection, 1.4 mg/m2 each time, intravenous injection (2 \~ 5 min)
Study NCT06503107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanobody-based biepitope BCMA-targeting CAR-T cells
Description: Each patient will receive nanobody-based biepitope BCMA-targeting CAR-T cell by intravenous infusion on day 0.
Study NCT04840784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETH-155008
Description: ETH-155008 is an orally bioavailable, potent Pim-3 and CDK4/6 dual kinase inhibitor.~Dosage form:10mg, 20 mg and 40 mg, tablets. ETH-155008 tablets should be taken while fasting, either 1 hour before or 2 hours after a meal.
Study NCT06304909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine injection
Description: Dexmedetomidine group will receive 0.5 mcg/kg
Study NCT06313125 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3-dimensional foot-ankle extension exercises
Description: In three-dimensional foot-ankle extension exercises, an elastic band will be used to create resistance to the movement and the intensity/severity of the exercise will be between 13 (somewhat difficult) and 15 (difficult) according to the perceived difficulty level on the Borg scale. Exercises will begin with red (light) tape; Progression will be achieved by moving to a higher level band color \[green (medium) and blue (difficult) in that order\] every two weeks. Exercises will be performed 3 days a week (2 days supervised, 1 day at home), in 3 sets of 10 repetitions, and a 1-minute rest period will be given between sets to reduce fatigue. Short-foot exercises will be performed in 3 sets of 15 repetitions, with a 45-second rest period between sets, every day a week (2 days/week with a physiotherapist; 5 days/week at home) for 6 weeks.
Study NCT06313125 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clam exercise
Description: In three-dimensional foot-ankle extension exercises and clam exercise, an elastic band will be used to create resistance to the movement and the intensity/severity of the exercise will be between 13 (somewhat difficult) and 15 (difficult) according to the perceived difficulty level on the Borg scale. Exercises will begin with red (light) tape; Progression will be achieved by moving to a higher level band color \[green (medium) and blue (difficult) in that order\] every two weeks. Exercises will be performed 3 days a week (2 days supervised, 1 day at home), in 3 sets of 10 repetitions, and a 1-minute rest period will be given between sets to reduce fatigue. Short-foot exercises will be performed in 3 sets of 15 repetitions, with a 45-second rest period between sets, every day a week (2 days/week with a physiotherapist; 5 days/week at home) for 6 weeks.
Study NCT06313125 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Short-foot exercise
Description: In clam exercise, an elastic band will be used to create resistance to the movement and the intensity/severity of the exercise will be between 13 (somewhat difficult) and 15 (difficult) according to the perceived difficulty level on the Borg scale. Exercises will begin with red (light) tape; Progression will be achieved by moving to a higher level band color \[green (medium) and blue (difficult) in that order\] every two weeks. Exercises will be performed 3 days a week (2 days supervised, 1 day at home), in 3 sets of 10 repetitions, and a 1-minute rest period will be given between sets to reduce fatigue. Short-foot exercises will be performed in 3 sets of 15 repetitions, with a 45-second rest period between sets, every day a week (2 days/week with a physiotherapist; 5 days/week at home) for 6 weeks.
Study NCT06313125 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short-foot exercise
Description: In clam exercise, an elastic band will be used to create resistance to the movement and the intensity/severity of the exercise will be between 13 (somewhat difficult) and 15 (difficult) according to the perceived difficulty level on the Borg scale. Exercises will begin with red (light) tape; Progression will be achieved by moving to a higher level band color \[green (medium) and blue (difficult) in that order\] every two weeks. Exercises will be performed 3 days a week (2 days supervised, 1 day at home), in 3 sets of 10 repetitions, and a 1-minute rest period will be given between sets to reduce fatigue. Short-foot exercises will be performed in 3 sets of 15 repetitions, with a 45-second rest period between sets, every day a week (2 days/week with a physiotherapist; 5 days/week at home) for 6 weeks.
Study NCT06371443 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sucking and swallowing exercises
Description: Sucking-swallowing exercises were applied to premature infants in the experimental group (n=41) for 14 days, once a day, 12 minutes before feeding.
Study NCT05819099 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: An Intelligent Endoscopic Diagnosis System Developed and Verified Based on Deep Learning
Description: This study will compare the established AI model with the diagnostic results of endoscopists to evaluate the clinical auxiliary value of the model for endoscopists.
Study NCT05654584 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic sleeve gastrectomy
Description: Laparoscopic sleeve gastrectomy surgery will be performed by a single surgeon.
Study NCT06337214 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine Therapy Program for Reinforcing Vital Energy
Description: Comparing cancer patients who have participated in the program with those who have not, this study will examine differences in two types of quality of life questionnaires and constitution between the two groups.
Study NCT05178576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gevokizumab
Description: 120mg IV on day 1 of every 28-day cycle for 1 year (maximum of 13 cycles)
Study NCT05178576 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Signatera test
Description: ctDNA monitoring at weeks 8, 12, 24, 36, 48, 60 and 72 unless disease recurrence is documented.
Study NCT06544070 — intervention group
Intervention type: DEVICE
Intervention: Entia Liberty System
Description: Participants will donate finger-prick blood samples to be tested on the Entia Liberty System. The results will not be used to inform clinical decisions or affect routine clinical care in any way.